An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]

Peer Review reports

Original Submission
15 Aug 2012	Submitted	Original manuscript
2 Nov 2012	Reviewed	Reviewer Report - Stephen Falk
13 Nov 2012	Reviewed	Reviewer Report - Paul Ross
13 Nov 2012	Reviewed	Reviewer Report - raffaele palmirotta
16 Dec 2012	Author responded	Author comments - Cassandra Cordwell
Resubmission - Version 2
16 Dec 2012	Submitted	Manuscript version 2
Publishing
8 Mar 2013	Editorially accepted
15 Mar 2013	Article published	10.1186/1471-2407-13-120

Back to article page